BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 14728049)

  • 1. Role of metabolically active drugs in the management of ischemic heart disease.
    Schofield RS; Hill JA
    Am J Cardiovasc Drugs; 2001; 1(1):23-35. PubMed ID: 14728049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ischemic heart disease: metabolic approaches to management.
    Pauly DF; Pepine CJ
    Clin Cardiol; 2004 Aug; 27(8):439-41. PubMed ID: 15346837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic modulators for chronic cardiac ischemia.
    Parang P; Singh B; Arora R
    J Cardiovasc Pharmacol Ther; 2005 Dec; 10(4):217-23. PubMed ID: 16382258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The metabolic treatment of patients with coronary artery disease: effects on quality of life and effort angina.
    César LA; Gowdak LH; Mansur AP
    Curr Pharm Des; 2009; 15(8):841-9. PubMed ID: 19275648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
    Lee L; Horowitz J; Frenneaux M
    Eur Heart J; 2004 Apr; 25(8):634-41. PubMed ID: 15084367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
    Rupp H; Zarain-Herzberg A; Maisch B
    Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation.
    Sack MN; Yellon DM
    J Am Coll Cardiol; 2003 Apr; 41(8):1404-7. PubMed ID: 12706939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
    Belardinelli R
    Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranolazine: effects on ischemic heart.
    Rognoni A; Barbieri L; Cavallino C; Bacchini S; Veia A; Degiovanni A; Rametta F; Nardi F; Lazzero M; Lupi A; Bongo AS
    Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):197-203. PubMed ID: 23961914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectors of fatty acid oxidation reduction: promising new anti-ischaemic agents.
    Grynberg A
    Curr Pharm Des; 2005; 11(4):489-509. PubMed ID: 15725067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography.
    Mody FV; Singh BN; Mohiuddin IH; Coyle KB; Buxton DB; Hansen HW; Sumida R; Schelbert HR
    Am J Cardiol; 1998 Sep; 82(5A):42K-49K. PubMed ID: 9737485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial fatty acid oxidation inhibitors for stable angina.
    Stanley WC
    Expert Opin Investig Drugs; 2002 May; 11(5):615-29. PubMed ID: 11996644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism.
    Lopaschuk GD
    Am J Cardiol; 1998 Sep; 82(5A):14K-17K. PubMed ID: 9737481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
    MacInnes A; Fairman DA; Binding P; Rhodes Ja; Wyatt MJ; Phelan A; Haddock PS; Karran EH
    Circ Res; 2003 Aug; 93(3):e26-32. PubMed ID: 12869391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
    Chaitman BR
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S47-64. PubMed ID: 15378131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic management of ischaemic heart disease.
    Chierchia SL; Fragasso G
    Eur Heart J; 1993 Nov; 14 Suppl G():2-5. PubMed ID: 7904560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic support for the heart: complementary therapy for heart failure?
    Heggermont WA; Papageorgiou AP; Heymans S; van Bilsen M
    Eur J Heart Fail; 2016 Dec; 18(12):1420-1429. PubMed ID: 27813339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism].
    Lopaschuk GD
    Presse Med; 1998 Dec; 27(39):2100-4. PubMed ID: 9893703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease.
    Mehta PK; Goykhman P; Thomson LE; Shufelt C; Wei J; Yang Y; Gill E; Minissian M; Shaw LJ; Slomka PJ; Slivka M; Berman DS; Bairey Merz CN
    JACC Cardiovasc Imaging; 2011 May; 4(5):514-22. PubMed ID: 21565740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced preservation of acutely ischemic myocardium and improved clinical outcomes using glucose-insulin-potassium (GIK) solutions.
    Lazar HL
    Am J Cardiol; 1997 Aug; 80(3A):90A-93A. PubMed ID: 9293960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.